Fungal Foot Infections Drug Development Pipeline Review, 2018

This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the therapeutics under development for onychomycosis (Tinea unguium) and athlete’s foot (Tinea pedis), and key players active within these indications.

Both of these indications are fungal infections primarily affecting the feet. Onychomycosis affects the nails, whereas athlete’s foot affects the skin under the feet and between the toes. Common symptoms include discomfort, itchiness, and – in the case of onychomycosis – discoloured and disfigured nails. Combined, these infections affect around 25% of the adult population.

There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology. There are a total of 25 products in development for both indications, by 24 companies.

Scope

– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies mentioned

Almirall SA

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Blueberry Therapeutics Ltd

Broda Tech LLC

Dermala Inc

Eisai Co Ltd

Helix BioMedix Inc

Hexima Ltd

Kaken Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Moberg Pharma AB

NAL Pharmaceuticals Ltd

Novabiotics Ltd

Novan Inc

Novoteris LLC

Onychomycosis (Tinea Unguium)

Sanotize Research And Development Corp

Tinea pedis (Athlete Foot)

Viamet Pharmaceuticals Inc

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Fungal Foot Infections Report Coverage 7

2.2 Onychomycosis (Tinea Unguium) - Overview 7

2.3 Tinea pedis (Athlete Foot) - Overview 7

3 Therapeutics Development 8

3.1 Onychomycosis (Tinea Unguium) 8

3.2 Tinea pedis (Athlete Foot) 12

4 Therapeutics Assessment 15

4.1 Onychomycosis (Tinea Unguium) 15

4.2 Tinea pedis (Athlete Foot) 21

5 Companies Involved in Therapeutics Development 26

5.1 Onychomycosis (Tinea Unguium) 26

5.2 Tinea pedis (Athlete Foot) 32

6 Dormant Projects 36

6.1 Onychomycosis (Tinea Unguium) 36

6.2 Tinea pedis (Athlete Foot) 38

7 Discontinued Products 39

7.1 Onychomycosis (Tinea Unguium) 39

8 Product Development Milestones 40

8.1 Onychomycosis (Tinea Unguium) 40

8.2 Tinea pedis (Athlete Foot) 50

9 Appendix 57

9.1 Methodology 57

9.2 Coverage 57

9.3 Secondary Research 57

9.4 Primary Research 57

9.5 Expert Panel Validation 57

9.6 Contact Us 58

9.7 Disclaimer 58

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Onychomycosis (Tinea Unguium) 8

Table 2: Number of Products under Development by Companies, Onychomycosis (Tinea Unguium) 10

Table 3: Products under Development by Companies, Onychomycosis (Tinea Unguium) 11

Table 4: Number of Products under Development for Tinea pedis (Athlete Foot) 12

Table 5: Number of Products under Development by Companies, Tinea pedis (Athlete Foot) 13

Table 6: Products under Development by Companies, Tinea pedis (Athlete Foot) 14

Table 7: Number of Products by Stage and Target, Onychomycosis (Tinea Unguium) 16

Table 8: Number of Products by Stage and Mechanism of Action, Onychomycosis (Tinea Unguium) 17

Table 9: Number of Products by Stage and Route of Administration, Onychomycosis (Tinea Unguium) 19

Table 10: Number of Products by Stage and Molecule Type, Onychomycosis (Tinea Unguium) 20

Table 11: Number of Products by Stage and Target, Tinea pedis (Athlete Foot) 22

Table 12: Number of Products by Stage and Mechanism of Action, Tinea pedis (Athlete Foot) 23

Table 13: Number of Products by Stage and Route of Administration, Tinea pedis (Athlete Foot) 25

Table 14: Number of Products by Stage and Molecule Type, Tinea pedis (Athlete Foot) 25

Table 15: Onychomycosis (Tinea Unguium) – Pipeline by Almirall SA 26

Table 16: Onychomycosis (Tinea Unguium) – Pipeline by Blueberry Therapeutics Ltd 27

Table 17: Onychomycosis (Tinea Unguium) – Pipeline by Dermala Inc 27

Table 18: Onychomycosis (Tinea Unguium) – Pipeline by Eisai Co Ltd 27

Table 19: Onychomycosis (Tinea Unguium) – Pipeline by Helix BioMedix Inc 28

Table 20: Onychomycosis (Tinea Unguium) – Pipeline by Hexima Ltd 28

Table 21: Onychomycosis (Tinea Unguium) – Pipeline by Kaken Pharmaceutical Co Ltd 29

Table 22: Onychomycosis (Tinea Unguium) – Pipeline by Meiji Seika Pharma Co Ltd 29

Table 23: Onychomycosis (Tinea Unguium) – Pipeline by Moberg Pharma AB 30

Table 24: Onychomycosis (Tinea Unguium) – Pipeline by NAL Pharmaceuticals Ltd 30

Table 25: Onychomycosis (Tinea Unguium) – Pipeline by Novabiotics Ltd 31

Table 26: Onychomycosis (Tinea Unguium) – Pipeline by Novan Inc 31

Table 27: Onychomycosis (Tinea Unguium) – Pipeline by Viamet Pharmaceuticals Inc 32

Table 28: Tinea pedis (Athlete Foot) – Pipeline by Astellas Pharma Inc 32

Table 29: Tinea pedis (Athlete Foot) – Pipeline by Biolab Farmaceutica Ltda 33

Table 30: Tinea pedis (Athlete Foot) – Pipeline by Blueberry Therapeutics Ltd 33

Table 31: Tinea pedis (Athlete Foot) – Pipeline by Broda Tech LLC 34

Table 32: Tinea pedis (Athlete Foot) – Pipeline by Novan Inc 34

Table 33: Tinea pedis (Athlete Foot) – Pipeline by Novoteris LLC 35

Table 34: Tinea pedis (Athlete Foot) – Pipeline by Sanotize Research And Development Corp 35

Table 35: Tinea pedis (Athlete Foot) – Pipeline by Viamet Pharmaceuticals Inc 35

Table 36: Onychomycosis (Tinea Unguium) – Dormant Projects 36

Table 37: Tinea pedis (Athlete Foot) – Dormant Projects 38

Table 38: Onychomycosis (Tinea Unguium) – Discontinued Products 39

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Onychomycosis (Tinea Unguium) 8

Figure 2: Number of Products under Development by Companies, Onychomycosis (Tinea Unguium) 9

Figure 3: Number of Products under Development for Tinea pedis (Athlete Foot) 12

Figure 4: Number of Products under Development by Companies, Tinea pedis (Athlete Foot) 13

Figure 5: Number of Products by Targets, Onychomycosis (Tinea Unguium) 15

Figure 6: Number of Products by Stage and Targets, Onychomycosis (Tinea Unguium) 15

Figure 7: Number of Products by Mechanism of Actions, Onychomycosis (Tinea Unguium) 16

Figure 8: Number of Products by Stage and Mechanism of Actions, Onychomycosis (Tinea Unguium) 17

Figure 9: Number of Products by Routes of Administration, Onychomycosis (Tinea Unguium) 18

Figure 10: Number of Products by Stage and Routes of Administration, Onychomycosis (Tinea Unguium) 18

Figure 11: Number of Products by Molecule Types, Onychomycosis (Tinea Unguium) 19

Figure 12: Number of Products by Stage and Molecule Types, Onychomycosis (Tinea Unguium) 20

Figure 13: Number of Products by Targets, Tinea pedis (Athlete Foot) 21

Figure 14: Number of Products by Stage and Targets, Tinea pedis (Athlete Foot) 21

Figure 15: Number of Products by Mechanism of Actions, Tinea pedis (Athlete Foot) 22

Figure 16: Number of Products by Stage and Mechanism of Actions, Tinea pedis (Athlete Foot) 23

Figure 17: Number of Products by Routes of Administration, Tinea pedis (Athlete Foot) 24

Figure 18: Number of Products by Stage and Routes of Administration, Tinea pedis (Athlete Foot) 24

Figure 19: Number of Products by Stage and Molecule Types, Tinea pedis (Athlete Foot) 25

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports